# T-regulatory Cells in ALS

> **NCT04055623** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 12 (estimated)

## Conditions studied

- ALS (Amyotrophic Lateral Sclerosis)

## Interventions

- **BIOLOGICAL:** Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
- **OTHER:** Monthly placebo infusions + 3 times per week placebo injections
- **BIOLOGICAL:** Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections

## Key facts

- **NCT ID:** NCT04055623
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-07
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055623, "T-regulatory Cells in ALS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04055623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*